Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Saad Z. Usmani"'
Autor:
Maria-Victoria Mateos, Mihaela Obreja, Kihyun Kim, Anita Zahlten-Kumeli, Ajay K. Nooka, Andrew Spencer, Katja Weisel, Olga Samoylova, Sebastian Grosicki, Sosana Delimpasi, Kenshi Suzuki, Christopher P. Venner, Thierry Facon, Saad Z. Usmani, Hang Quach
Publikováno v:
British Journal of Haematology. 194:784-788
Autor:
Hans C. Lee, Saad Z. Usmani, Robert M. Rifkin, Dasha Cherepanov, Evangelos Terpos, Faith E. Davies, Dorothy Romanus, Antonio Palumbo, Aditya Raju, Jesus G. Berdeja, Dawn Marie Stull, Noemi Puig, Jorge Vela-Ojeda, Rafat Abonour, Xavier Leleu, Hui Huang, Ajai Chari, Eileen Farrelly, Mario Boccadoro, Gordon Cook, Katja Weisel, Gareth J. Morgan, Caitlin Costello, Jeffrey A. Zonder, Marlo Blazer, Michael A. Thompson, Roman Hájek
Publikováno v:
Annals of Hematology
Multiple available combinations of proteasome inhibitors, immunomodulators (IMIDs), and monoclonal antibodies are shifting the relapsed/refractory multiple myeloma (RRMM) treatment landscape. Lack of head-to-head trials of triplet regimens highlights
Autor:
Xavier Leleu, Zandra Klippel, David S. Siegel, Maria-Victoria Mateos, Meletios A. Dimopoulos, Hang Quach, Ola Landgren, Saad Z. Usmani, Katja Weisel, Anita Zahlten-Kumeli, Hui Yang
Publikováno v:
The Lancet. 396:186-197
Summary Background Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy wit
Autor:
Ruben Niesvizky, Saurabh Chhabra, Chatchada Karanes, Robert F. Cornell, Yihua Lee, Saad Z. Usmani, Jeffrey Matous, Robert K. Stuart, Larry D. Anderson, Jason Valent, Cristina Gasparetto, Zeena Salman, Emily Liu, Ajai Chari, Matthew A. Lunning, Chaim Shustik, Saulius Girnius
Publikováno v:
Hematological Oncology
Patients with multiple myeloma (MM) inevitably relapse on initial treatment regimens, and novel combination therapies are needed. Ibrutinib is a first‐in‐class, once‐daily inhibitor of Bruton's tyrosine kinase, an enzyme implicated in growth an
Publikováno v:
Expert review of hematology. 14(12)
INTRODUCTION: Despite the development of new therapeutic agents, relapsed/refractory multiple myeloma (RRMM) is associated with poor survival outcomes. Furthermore, many patients develop resistance to immunomodulatory drugs (IMiD), creating a need fo
Autor:
Jeffrey A. Zonder, Alexandra Jungova, Magda Bařinová, Katja Weisel, Roman Hájek, Evangelos Terpos, Frits van Rhee, Rafat Abonour, Jorge Vela-Ojeda, Michael A. Thompson, Robert M. Rifkin, Jin Lu, Jennifer Elliott, Xavier Leleu, Vladimir Maisnar, Kenny Galvez, Ajai Chari, Faith E. Davies, Lenka Capkova, Jiří Minařík, Caitlin Costello, Lucie Brozova, Jan Straub, Jesus G. Berdeja, Noemi Puig, Hans C. Lee, Kaili Ren, Mario Boccadoro, Jiří Šilar, Saad Z. Usmani, Dawn Marie Stull, Gordon Cook, Matyáš Kuhn, Luděk Pour, Andrew Spencer, Vania Tm Hungria
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbb2eb25f28b45fad8a319815d33ed8e
http://hdl.handle.net/10261/261619
http://hdl.handle.net/10261/261619
Autor:
Ayman Saad, Tamila L. Kindwall-Keller, Raphael Fraser, Sathish Kumar Gopalakrishnan, Rammurti T. Kamble, Anita D'Souza, Cesar O. Freytes, Melhem Solh, Robert A. Kyle, Hillard M. Lazarus, Jesus G. Berdeja, Siddhartha Ganguly, Robert Peter Gale, Taiga Nishihori, Parameswaran Hari, Kenneth R. Meehan, Tomer M Mark, Saad Z. Usmani, Cindy Lee, Miguel Angel Diaz, Usama Gergis, Binod Dhakal, Abraham S. Kanate, Shaji Kumar, Amer Assal, Omar Davila, Emma C. Scott, Frederick L. Locke, Yago Nieto, Cristina Gasparetto, Gerhard C. Hildebrandt, Bipin N. Savani, Nina Shah, Sachiko Seo
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
The revised International Staging System (R-ISS) combines ISS with genetic markers and lactate dehydrogenase and can prognosticate newly diagnosed multiple myeloma (MM). Early relapse (
Autor:
Michaela Liedtke, Amarendra K. Neppalli, Elizabeth McGehee, Ehsan Malek, Saad Z. Usmani, Robert F. Cornell, Swapna Narayana, Ankit Kansagra, Natalie S. Callander, Elvira Umyarova, Parameswaran Hari, Arjun Lakshman, Ridhi Gupta, Barry Paul, Joshua Mansour, Zhubin Gahvari, Ujjawal H. Gandhi, William Varnado, Alyssa Barnstead, Saurabh Chhabra, Mark A. Fiala, Emma C. Scott, Megan Jagosky, Saranya Kodali, Ravi Vij, Yubin Kang, Kelly N. Godby, Luciano J. Costa, Shaji Kumar
Publikováno v:
Leukemia. 33:2266-2275
The introduction of CD38-targeting monoclonal antibodies (CD38 MoABs), daratumumab and isatuximab, has significantly impacted the management of patients with multiple myeloma (MM). Outcomes of patients with MM refractory to CD38 MoABs have not been d
Autor:
Meletios-Athanasios Dimopoulos, Ian McFadden, Hang Quach, Maria-Victoria Mateos, Akeem Yusuf, Andrew Spencer, Saad Z. Usmani, Mihaela Obreja, Rafael Fonseca, Monica Khurana
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S150-S151
Background Widespread use of lenalidomide (Len) as standard first-line therapy for patients (pts) with multiple myeloma (MM) has resulted in a need for Len-sparing treatments in relapsed/refractory (RR) MM. The CANDOR study (NCT03158688) demonstrated
Autor:
Sarah Norek, Reed Friend, Saad Z. Usmani, Manisha Bhutani, Lawrence J. Druhan, David M. Foureau, Katherine Rigby, James T. Symanowski, Barry Paul, Mallory Tucker, Myra M. Robinson, Mauricio Pineda-Roman, Shebli Atrash, Peter M. Voorhees
Publikováno v:
Blood. 138:2739-2739
Introduction: The treatment for RRMM in first relapse typically involves a triplet combination, with choice influenced by the type of treatment already received, and the initial response. Elotuzumab (Elo), an anti-SLAMF7 immunostimulatory monoclonal